4-isopropoxyquinoline | 141813-10-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-isopropoxyquinoline
• 英文别名: 4-(1-Methylethoxy)quinoline；4-propan-2-yloxyquinoline
• CAS: 141813-10-7
• 化学式: C₁₂H₁₃NO
• 分子量: 187.241
• InChiKey: RXXGWCLPRJOXOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-苯甲酰基-1,2-二氢-2-喹啉甲腈 、 异丙醇 在 sodium hydroxide 、 溴 作用下， 生成 4-isopropoxyquinoline
  参考文献：
  名称：

  Synthesis of 4-Alkoxyquinolines from Quinoline Reissert Compounds

  摘要：

  The quinoline Reissert compound (5a) was converted to 1-benzoyl-3-bromo-2-cyano-1, 2, 3, 4-tetrahydro-4-methoxyquinoline (6a) by successive treatment in methanol with bromine and aq. sodium carbonate. Hydrolysis of 6a with hydrochrolic acid gave 3-bromoquinoline (4; R = H), but that with aq. sodium hydroxide afforded 4-methoxyquinoline (7a). Reissert compounds derived from some quinoline derivatives (5) gave the corresponding 4-methoxyquinolines (7) through tetrahydroquinolines (6) in a similar way.

  DOI：

  10.3987/com-91-5945

文献信息

• Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases
  申请人：Li Yun Long

  公开号：US20080167288A1

  公开（公告）日：2008-07-10

  The present invention provides compounds of the formula: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了公式的化合物：其对映异构体、非对映异构体、混合物、前药、晶体形式、非晶体形式、无定形形式、溶剂化物、代谢物和药学上可接受的盐，其中环A的取代基在下面的披露中被完全定义。公式化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和脱落酶，可用于治疗风湿性关节炎、银屑病、肿瘤性疾病、过敏和所有需要抑制MMP的疾病。
• SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：Li Yun-Long

  公开号：US20110224189A1

  公开（公告）日：2011-09-15

  The present invention provides compounds of the formula: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了化合物的公式：其对映异构体，对映体混合物，前药，晶体形式，非晶体形式，无定形形式，其溶剂化物，代谢产物以及药学上可接受的盐，其中环A的取代基在以下披露中完全定义。公式化合物是金属蛋白酶抑制剂，例如基质金属蛋白酶和剪切酶，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要抑制MMP的疾病中有用。
• Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
  申请人：Incyte Corporation

  公开号：EP2264030A1

  公开（公告）日：2010-12-22

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了式 I 的化合物： 其对映体、非对映体、外消旋混合物、原药、结晶形式、非结晶形式、无定形形式、其溶解物、其代谢物和药学上可接受的盐，其中环 A 取代基团在以下公开内容中完全定义。式 I 的化合物是基质金属蛋白酶和脱落酶等金属蛋白酶的抑制剂，可用于治疗类风湿性关节炎、银屑病、肿瘤性疾病、过敏症等疾病以及所有需要抑制 MMPs 的疾病。
• US7491724B2
  申请人：——

  公开号：US7491724B2

  公开（公告）日：2009-02-17
• US7973041B2
  申请人：——

  公开号：US7973041B2

  公开（公告）日：2011-07-05